These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 38987605)
1. Cellular adaptation to cancer therapy along a resistance continuum. França GS; Baron M; King BR; Bossowski JP; Bjornberg A; Pour M; Rao A; Patel AS; Misirlioglu S; Barkley D; Tang KH; Dolgalev I; Liberman DA; Avital G; Kuperwaser F; Chiodin M; Levine DA; Papagiannakopoulos T; Marusyk A; Lionnet T; Yanai I Nature; 2024 Jul; 631(8022):876-883. PubMed ID: 38987605 [TBL] [Abstract][Full Text] [Related]
2. Mathematical models of cell phenotype regulation and reprogramming: Make cancer cells sensitive again! Wooten DJ; Quaranta V Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):167-175. PubMed ID: 28396217 [TBL] [Abstract][Full Text] [Related]
3. Cancer Plasticity: The Role of mRNA Translation. Lee LJ; Papadopoli D; Jewer M; Del Rincon S; Topisirovic I; Lawrence MG; Postovit LM Trends Cancer; 2021 Feb; 7(2):134-145. PubMed ID: 33067172 [TBL] [Abstract][Full Text] [Related]
4. Emerging Mechanisms by which EMT Programs Control Stemness. Wilson MM; Weinberg RA; Lees JA; Guen VJ Trends Cancer; 2020 Sep; 6(9):775-780. PubMed ID: 32312682 [TBL] [Abstract][Full Text] [Related]
5. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Bhat GR; Sethi I; Sadida HQ; Rah B; Mir R; Algehainy N; Albalawi IA; Masoodi T; Subbaraj GK; Jamal F; Singh M; Kumar R; Macha MA; Uddin S; Akil ASA; Haris M; Bhat AA Cancer Metastasis Rev; 2024 Mar; 43(1):197-228. PubMed ID: 38329598 [TBL] [Abstract][Full Text] [Related]
6. Reprogramming to developmental plasticity in cancer stem cells. O'Brien-Ball C; Biddle A Dev Biol; 2017 Oct; 430(2):266-274. PubMed ID: 28774727 [TBL] [Abstract][Full Text] [Related]
7. Semaphorins as Regulators of Phenotypic Plasticity and Functional Reprogramming of Cancer Cells. Gurrapu S; Tamagnone L Trends Mol Med; 2019 Apr; 25(4):303-314. PubMed ID: 30824197 [TBL] [Abstract][Full Text] [Related]
8. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer. Ravindran Menon D; Hammerlindl H; Torrano J; Schaider H; Fujita M Theranostics; 2020; 10(14):6261-6277. PubMed ID: 32483452 [TBL] [Abstract][Full Text] [Related]
9. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Shaffer SM; Dunagin MC; Torborg SR; Torre EA; Emert B; Krepler C; Beqiri M; Sproesser K; Brafford PA; Xiao M; Eggan E; Anastopoulos IN; Vargas-Garcia CA; Singh A; Nathanson KL; Herlyn M; Raj A Nature; 2017 Jun; 546(7658):431-435. PubMed ID: 28607484 [TBL] [Abstract][Full Text] [Related]
10. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. Falletta P; Sanchez-Del-Campo L; Chauhan J; Effern M; Kenyon A; Kershaw CJ; Siddaway R; Lisle R; Freter R; Daniels MJ; Lu X; Tüting T; Middleton M; Buffa FM; Willis AE; Pavitt G; Ronai ZA; Sauka-Spengler T; Hölzel M; Goding CR Genes Dev; 2017 Jan; 31(1):18-33. PubMed ID: 28096186 [TBL] [Abstract][Full Text] [Related]
12. Identification of the specific epigenetic alterations associated with chemo-resistance via reprogramming of cancer cells. Kim JJ; Rai R Med Hypotheses; 2015 Dec; 85(6):710-4. PubMed ID: 26527497 [TBL] [Abstract][Full Text] [Related]
13. The EMT spectrum and therapeutic opportunities. Voon DC; Huang RY; Jackson RA; Thiery JP Mol Oncol; 2017 Jul; 11(7):878-891. PubMed ID: 28544151 [TBL] [Abstract][Full Text] [Related]
14. Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas. Navas T; Kinders RJ; Lawrence SM; Ferry-Galow KV; Borgel S; Hollingshead MG; Srivastava AK; Alcoser SY; Makhlouf HR; Chuaqui R; Wilsker DF; Konaté MM; Miller SB; Voth AR; Chen L; Vilimas T; Subramanian J; Rubinstein L; Kummar S; Chen AP; Bottaro DP; Doroshow JH; Parchment RE Cancer Res; 2020 Jan; 80(2):304-318. PubMed ID: 31732654 [TBL] [Abstract][Full Text] [Related]
17. Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression. Nishino H; Takano S; Yoshitomi H; Suzuki K; Kagawa S; Shimazaki R; Shimizu H; Furukawa K; Miyazaki M; Ohtsuka M Cancer Med; 2017 Nov; 6(11):2686-2696. PubMed ID: 28960866 [TBL] [Abstract][Full Text] [Related]
18. Cancer cells undergoing epigenetic transition show short-term resistance and are transformed into cells with medium-term resistance by drug treatment. Poojan S; Bae SH; Min JW; Lee EY; Song Y; Kim HY; Sim HW; Kang EK; Kim YH; Lee HO; Hong Y; Park WY; Jang H; Hong KM Exp Mol Med; 2020 Jul; 52(7):1102-1115. PubMed ID: 32661348 [TBL] [Abstract][Full Text] [Related]
19. Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance. Gupta PB; Pastushenko I; Skibinski A; Blanpain C; Kuperwasser C Cell Stem Cell; 2019 Jan; 24(1):65-78. PubMed ID: 30554963 [TBL] [Abstract][Full Text] [Related]
20. The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment. Ma B; Wells A; Clark AM Semin Cancer Biol; 2020 Feb; 60():138-147. PubMed ID: 31376430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]